• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Slides for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
FDA
  
FDA Core Presentations for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 332KB)
 
 
Eli Lilly and Co.
 
Eli Lilly Core Presentations, Erbitux (cetuximab), for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 212KB)
 
GlaxoSmithKline
 
GSK Core and Backup Presentations, Bexxar (tositumomab and Iodine I 131 tositumomab), for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 223KB)
 
GSK Core Presentations, Arranon (nelarabine) Injection, for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 127KB)
 
Genzyme Corp.
 
Genzyme Core Presentations, Clolar (clofarabine), for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 252KB)
 
Amgen, Inc.
 
Amgen Core Presentations, Vectibix (panitumumab), for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 481KB)
 
Novartis Pharmaceuticals Corp.
 
Novartis Core Presentations, Gleevec (imatinib mesylate) Tablets, for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 149KB)
 
Guest Speaker
  
Speaker Core Presentations for the February 8, 2011 Meeting of the Oncologic Drugs Advisory Committee (PDF – 288KB)